Drug Profile
Research programme: tissue regeneration therapy - Nanotope
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nanotope
- Class
- Mechanism of Action Angiogenesis inducing agents; Bone development stimulants; Cartilage replacements; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone disorders; Cartilage disorders; Peripheral arterial disorders; Spinal cord injuries; Wounds
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cartilage-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Peripheral-arterial-disorders in USA (Parenteral)